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Considerations for Translation
of Tissue Engineered
Fibrocartilage From Bench
to Bedside
Fibrocartilage is found in the knee meniscus, the temporomandibular joint (TMJ) disk,
the pubic symphysis, the annulus fibrosus of intervertebral disk, tendons, and ligaments.
These tissues are notoriously difficult to repair due to their avascularity, and limited clin-
ical repair and replacement options exist. Tissue engineering has been proposed as a
route to repair and replace fibrocartilages. Using the knee meniscus and TMJ disk as
examples, this review describes how fibrocartilages can be engineered toward translation
to clinical use. Presented are fibrocartilage anatomy, function, epidemiology, pathology,
and current clinical treatments because they inform design criteria for tissue engineered
fibrocartilages. Methods for how native tissues are characterized histomorphologically,
biochemically, and mechanically to set gold standards are described. Then provided is a
review of fibrocartilage-specific tissue engineering strategies, including the selection of
cell sources, scaffold or scaffold-free methods, and biochemical and mechanical
stimuli. In closing, the Food and Drug Administration (FDA) paradigm is discussed to
inform researchers of both the guidance that exists and the questions that remain to be
answered with regard to bringing a tissue engineered fibrocartilage product to the clinic.
[DOI: 10.1115/1.4042201]
Keywords: tissue engineering, fibrocartilage, translation, knee meniscus, temporoman-
dibular joint disk
1 Introduction
Cartilage is a connective tissue that is classified by its biochem-
ical properties into hyaline, elastic, and fibrous cartilage (also
referred to as fibrocartilage). Of these, fibrocartilage is marked by
the presence of type I collagen and traces of type II collagen.
Glycosaminoglycans (GAGs) are present in fibrocartilage, albeit
in lower amounts than in hyaline articular cartilage [1]. Areas in
the body containing fibrocartilage include the knee meniscus [2],
the temporomandibular joint (TMJ) disk [3], the pubic symphysis,
the annulus fibrosus of the intervertebral disk, tendons, and liga-
ments. Fibrocartilage undergoes a range of stresses including ten-
sion, compression, and shear in different areas of the body. Much
like hyaline articular cartilage, fibrocartilage has a naturally low
regenerative capacity due to its avascularity [1]. Fibrocartilages
are notoriously difficult to repair with limited clinical options. Tis-
sue engineering may be a route to provide novel clinical treat-
ments, but the pathway for these products can be ill-defined due to
the low number of Food and Drug Administration (FDA)-
approved cellular products. While FDA guidance documents exist
for human cells, tissues, and cellular and tissue-based products
(HCT/Ps) in general [4] and, specifically, for products intended to
repair or replace hyaline articular cartilage [5], an equivalent
document for fibrocartilage does not exist. Formation of clinically
relevant, tissue engineered fibrocartilages would require satisfying
a variety of design criteria and regulatory requirements. This
review uses the knee meniscus and TMJ disk fibrocartilages as
two examples to discuss how tissue engineered fibrocartilages
may be translated from the bench to bedside.
In Secs. 2–4, anatomy and structure–function relationships of
the knee meniscus and TMJ disk will be presented. Epidemiology
of these tissues and the causal pathologies that lead to specific
indications for current clinical treatments will be provided. Assays
for characterization for histomorphological, biochemical, and
mechanical properties of fibrocartilages will be explained.
Together, anatomy, function, epidemiology, pathology, current
clinical treatments, and characterization studies inform design cri-
teria for tissue engineered fibrocartilages. In context to these
design criteria, current tissue engineering methods for
fibrocartilage, specifically the meniscus and TMJ disk, will be dis-
cussed via subsections on the selection of cell source, a scaffold-
ing or scaffold-free approach, biochemical stimuli, and
mechanical stimuli. In addition, evaluation of tissue engineered
fibrocartilages and discussion of engineering a fibrocartilage spec-
trum will be provided. The final section of this paper will look
toward the translation of tissue engineered fibrocartilage and how
this type of product may be shepherded through the FDA para-
digm. A focus will be considerations for preclinical animal mod-
els and clinical trials. Future directions will be recommended,
motivation for FDA guidance will be discussed, and remaining
questions or concerns will be presented.
2 Fibrocartilage Types, Epidemiology, Pathology, and
Clinical Treatments
Fibrocartilage anatomy, function, epidemiology, and pathology
all inform how tissue engineered fibrocartilage should be designed
and made. Current clinical options and practices can inform how
tissue engineered fibrocartilage may be deployed in the clinical
setting and can, thus, inform design criteria as well. These are pro-
vided below.
2.1 The Knee Meniscus and Temporomandibular Joint
disc. In 2005, more than 46 million adults incurred over $353
billion in direct healthcare costs related to different rheumatic
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conditions in the U.S. alone [6]. These conditions encompass
those affecting fibrocartilages. Two fibrocartilages of high clinical
relevance are the knee menisci and TMJ disk. Knee menisci are
semicircular, wedge-shaped fibrocartilaginous tissues, located
between the distal femur and the tibial plateau (Fig. 1) that protect
articular cartilage via load distribution. The knee contains a
medial and a lateral meniscus (Fig. 1). Under compressive load,
the menisci’s wedge shape causes tension to develop, which is
resisted by circumferentially aligned collagen. A gradient of heal-
ing capabilities in the knee meniscus correlates with the degree of
vascularity, with the capacity for healing decreasing as one moves
closer to the innermost, avascular region (Fig. 1, white-white
region).
The TMJ is a ginglymoarthrodial joint that contains a fibrocarti-
laginous disk situated between the mandibular condyle on the
inferior side, and articular eminence and mandibular fossa on the
superior side (Fig. 1). The TMJ disk is biconcave and consists of
the anterior and posterior bands as well as the lateral, central, and
medial zones that are collectively referred to as the intermediate
zone (Fig. 1) [7]. The TMJ disk serves to increase congruity
between the eminence and fossa, to distribute load, and to aid in
joint lubrication [8]. The movement of the TMJ disk serves the
rotational motion of the joint primarily in the rotational axis dur-
ing normal mastication and the translational motion of the joint
when the mouth is opened wide. During typical movements of the
joint, loading patterns in the anterior portion of the mandibular
condyle and posterior portion of the articular eminence lead to
complex shear, compressive, and tensile forces on the fibrocartila-
ginous disk.
2.2 Epidemiology and Pathology. Meniscal lesions are the
most common intra-articular knee injuries and most frequent
cause of orthopedic surgical procedures in the U.S. [9]. This is
reflected by the size of the meniscus repair market, which in 2008
was anticipated to increase at a compound annual growth rate of
10.6% to an estimated $318 million in 2015 [10]. Previously
reported incidences of meniscal injury leading to meniscectomy
Fig. 1 Anatomy of the knee meniscus and TMJ disk. The anatomical structures of the knee
are shown, with the menisci depicted between the femur and tibia. The transverse view is
shown in the right panel, indicating the different vascular regions of each meniscus. The TMJ
disk is shown from a sagittal view between the mandibular condyle and the articular eminence
in an open jaw position. The disk from a transverse view is depicted in the right-hand panel.
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were noted at 61 per 100,000 persons [11], but damage to the
medial meniscus is significantly more prevalent than in the lateral
meniscus (81% and 19%, respectively) [11–17]. Injury to the lat-
eral meniscus, while less frequent, leads to the degeneration of
knee function, lower Lysholm scale scores—a scale from 0 to 100
that measures patient-reported pain where 100 represents a better
outcome with fewer symptoms or disability, and a higher rate of
instability when treated via meniscectomy as compared to menis-
cectomy of the medial meniscus [16,17].
Meniscal lesions are classified by their spatial alignment as ver-
tical longitudinal (or longitudinal), radial, oblique, complex (or
degenerative), and horizontal tears (Fig. 2). Complex tears are
more likely to arise with increasing age, while other tears are
more commonly attributed to traumatic injury. Oblique and verti-
cal longitudinal tears represent 81% of meniscal tears [18,19].
Vertical longitudinal tears run parallel to the long axis of the
meniscus and are perpendicular to the tibial plateau (Fig. 2).
These tears divide the circumferentially aligned collagen fibers
and are categorized as either complete or incomplete vertical lon-
gitudinal tears. The former is known as a bucket handle tear,
which more commonly affects the medial meniscus. Bucket han-
dle tears are often unstable and can cause mechanical symptoms
or locking of the knee [18], and are more amenable to repair if
found within a vascularized region of the meniscus [20].
Temporomandibular joint disorders (TMDs) encompass any
issue with the jaw and the muscles that control it. TMDs are the
second most common musculoskeletal condition resulting in pain
and disability [21] and cost an estimated $4 billion per annum in
healthcare in the U.S. alone. TMDs may cause pain in 20–25% of
adults worldwide [22]. A gender paradox exists with TMDs
because a 3.5-fold higher prevalence is seen in women than men
[23,24]. This gender paradox has been well studied and has been
hypothesized to occur due to hormone differences between gen-
ders [24]. TMD symptoms are wide-ranging, including clicking,
restricted or deviating range of motions, and cranial and/or mus-
cular pain [22].
Up to 70% of TMD patients suffer from internal derangement
(ID) of the disk [25], where the TMJ disk is displaced from its
normal anatomic position. Severe cases of ID are often presented
with focal thinning of the disk, with eventual progression to larger
areas of thinning or disk perforation (DP) (Fig. 2) [26].
Osteoarthritis (OA) often accompanies TMDs [27], but there is
conflicting evidence of a clear causal relationship between ID and
OA [28].
Epidemiological and economic data make the knee meniscus
and TMJ disk highly significant fibrocartilages for tissue engineer-
ing. When one considers the mechanical behaviors of the knee
meniscus and TMJ disk, and how these functions fail due to
pathology, many similarities begin to emerge. For example, both
fibrocartilages function under large magnitudes of mechanical
stress; engineered implants must be ready to bear similar loads.
While specific pathological features may differ for the knee
meniscus and TMJ disk (tears for the meniscus and thinning or
perforation for the TMJ disk), late-stage pathologies of both fibro-
cartilages are often treated by tissue removal without long-term
options for replacement, leading to joint degeneration. The simi-
larities lead to comparable design criteria for the tissue engineer-
ing of these fibrocartilages.
2.3 Current Clinical Treatments. Fibrocartilage treatments
usually follow a path of two stages: nonsurgical methods followed
by surgical intervention that range from minimally to highly inva-
sive procedures. Nonsurgical methods may include physical ther-
apy, analgesics for pain management, and behavioral
modification, and are indicated for early disease stages. If no
improvement in symptoms is shown, surgery may be indicated.
Surgical options for fibrocartilage are limited and progress rapidly
to final stage options, such as arthroplasty, beyond which, even
fewer options exist [29]. Tissue engineered fibrocartilage could
potentially bridge the gap between the early and end stages of
fibrocartilage pathology.
Initial diagnoses of knee meniscus injuries begin with clinical
examination using a variety of tests [18]. If a meniscal tear is
identified, the tear’s severity is categorized to determine treatment
which includes repair via arthroscopy, partial or full meniscec-
tomy, and allograft transplantation [18]. Therapeutic efficacy
varies by indication in part due to anatomy. For example, tears
found in the red-white region of the meniscus are more amenable
to repair than the white-white region due to the higher levels of
vascularity in that region [20]. If possible, meniscectomy should
be reserved for cases refractory to repair because meniscal repair
tends to yield better clinical outcomes than meniscectomy [30].
Fig. 2 Clinical indications of the knee meniscus and TMJ disk. Different clinical indications for the
meniscus are shown including five different tears: oblique, complex, vertical longitudinal, horizontal, and
radial tears. For the TMJ disk, disk thinning and DP are the clinical indications presented.
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Meniscectomy removes parts of the knee meniscus or cleans up
degenerative debris, leading to immediate pain relief, although
this is not always observed. Meniscectomy virtually guarantees
the emergence of OA [31]. While some meniscectomy patients
report pain relief, a statistically significant increase in quality of
life after meniscectomy over alternatives such as physical therapy
has not been observed, illustrating the limitations of fibrocartilage
removal without replacement [32–34].
Diagnosis of TMDs follows patients’ report of pain in the TMJ,
headaches behind or around the eyes, and pain spreading to the
temple, neck, ears, and shoulders [27]. Patients will often undergo
a physical exam and multiple imaging modalities, such as mag-
netic resonance imaging (MRI) and/or computed tomography
[22]. Although many TMJ symptoms can resolve themselves
[21,27], approximately 3–5% of TMD patients will require medi-
cal intervention in various forms.
Even in the most severe cases of TMDs, nonsurgical treatment is
preferred [27]. Surgical options for TMDs are limited but include
disk repositioning or discectomy with or without disk replacement
[22,35]. Hemiarthroplasty is replacement of the articulating joint sur-
face [36], most commonly the superior side in the TMJ with a vital-
lium alloy in the mandibular fossa-articular eminence region [37].
For certain indications such as ID, the disk can be repositioned in the
correct anatomic position. Another option is discectomy, where the
TMJ disk is removed. Postoperative follow-up in 3 years shows that
discectomy increases mandibular motion [38] but is also associated
with signs of degenerative changes including flattening of the articu-
lar surfaces and osteophytes [22,39]. Alloplastic disk replacements
have been studied including Teflon-Proplast- [40] and silicone-based
[22] implants. Biologic materials such as fat have also been explored
[41], but all have required follow-up intervention. When a substantial
portion of the joint is lost due to degeneration from trauma or signifi-
cant degeneration in the articulating surfaces, total joint reconstruc-
tion may be indicated [22]. Costochondral grafts are used to replace
the condyle in autologous TMJ reconstruction [42]. Alloplastic mate-
rials have been used in three FDA approved products [8,22] and
often require secondary surgery due to the average patient age and
resultant implant degradation [22].
As illustrated with the knee meniscus and TMJ disk, both non-
surgical and surgical options for fibrocartilage repair and replace-
ment are lacking in long-term efficacy. Nonsurgical methods
commonly treat symptoms and attempt to delay degeneration but
are often unsuccessful in doing so. Surgical methods can cause
degeneration in the joint space and commonly require additional
surgical follow-ups. An important consideration for tissue engi-
neers will be where and how engineered products might fit into
Fig. 3 Tissue engineering of fibrocartilage. Tissue engineering requires characterization of native cartilage from which
design criteria can be specified. Tissue engineering parameters such as selection of a cell source, choice of scaffold or
scaffold-free methodology, and use of biochemical or mechanical stimuli results in tissue engineered fibrocartilage which
is subsequently tested for appropriate properties. If design criteria are met, the tissue engineered fibrocartilage and
methodology used may move to preclinical animal models or the tissue engineering process might be reiterated to obtain
improved tissue engineered fibrocartilage.
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Fig. 4 The FDA paradigm. The FDA paradigm is outlined from tissue engineering studies to the postmarketing phase
with appropriate milestones for CBER and CDRH depicted.
Fig. 5 Cell morphology and collagen alignment of the knee meniscus and TMJ disk. (a) A representation of the wedge-
shape of the meniscus is depicted with the innermost region showing rounded, chondrocyte-like cells transitioning to
spindle-shaped, fibroblast-like cells toward the outermost region. Figure reused with permission from Springer Nature: Cel-
lular and Molecular Bioengineering [59]. (b) Scanning electron micrographs showing (1) the circumferential collagen align-
ment, (2) a close-up view depicting individual collagen fibers, (3) a cross section of a collagen bundle, and (4) the random
collagen orientation on the outer surfaces of the meniscus. Figure reused with permission from SAGE Publications: Pro-
ceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine [61]. (c) Ratio between fibro-
blasts and chondrocyte-like cells, and overall cellularity in the TMJ disk are reported, showing the posterior and anterior
bands have a higher proportion of fibroblasts when compared to the intermediate zone. Figure reused with permission from
Elsevier: Journal of Oral and Maxillofacial Surgery [47]. (d) Scanning electron micrographs of various regions of the TMJ
disk showing primarily anteroposterior alignment in the intermediate zone, while the anterior and posterior bands show cir-
cumferential alignment. Scale bars are 10 lm except for the lateral region where the scale bar represents 200 lm. Figure
reused with permission from Elsevier:Matrix Biology [56].
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existing treatment modalities, such as serving as a bridge between
early and late-stage surgical interventions.
2.4 Using Tissue Engineering for Fibrocartilage. The need
for interventions that can delay or arrest joint degeneration moti-
vates the development of tissue engineered fibrocartilages. In
early to midstage pathologies, such as a partial vertical longitudi-
nal tear in the knee meniscus or thinning of the TMJ disk, tissue
engineered fibrocartilage implants may be used to bolster failing
tissues to slow down or to arrest the degenerative process. Late-
stage pathology where fibrocartilage removal by meniscectomy or
discectomy is indicated may be combined with implantation of a
tissue engineered fibrocartilage replacement. While there is hope
for these strategies, there is currently a lack of tissue engineered
fibrocartilage products on the market. Sections 3–5 outline the
process of fibrocartilage tissue engineering (Fig. 3) and examine
the necessary steps for translating a tissue engineered fibrocarti-
lage product to clinical use (Fig. 4).
3 Characterization Studies of Fibrocartilages
Prior to carrying out tissue engineering studies, design criteria
must be acquired. These are determined via characterization stud-
ies of the native fibrocartilage using histology, immunohistochem-
istry (IHC), biochemical testing, and mechanical testing (Fig. 3).
Various animals commonly serve as models due to their anatomi-
cal, structural, and functional similarities to human tissues. Vari-
ous reviews and comparative studies in the literature discuss
different animal models and their similarities to human tissue for
both the knee meniscus [43,44] and TMJ disk [45,46] and should
be referenced to determine comparability. Test results establish
the gold standards toward which tissue engineers aim for in terms
of histomorphological, biochemical, and mechanical properties of
the engineered tissue. This section will provide guidance for the
aforementioned testing and will provide values for native knee
meniscus and TMJ disk properties that are relevant to tissue
engineering.
3.1 Histomorphological Properties. Histology and IHC
allow for examination of a tissue’s microscopic organization. In
fibrocartilage, the distribution of different cell types [47–50],
GAGs [48,50–54], and collagen [48,50,52–55] can be visualized
using hematoxylin staining, Safranin O staining with a Fast Green
counterstain, and Picrosirius Red staining, respectively. IHC uses
antibodies for more specific visualization of the aforementioned
items [53,56,57]. For example, multiple collagen types exist
within fibrocartilages, and these can be discerned using IHC.
Histology, IHC, and microscopy techniques (e.g., polarized
light, second harmonic generation) are used widely to elucidate
fibrocartilage properties. For example, different cell types reside
side-by-side in fibrocartilage, as seen in the meniscus where
chondrocyte-like cells exist in its inner region and transition to a
fibroblast-like phenotype in its outer region [58,59] (Fig. 5(a)). In
the TMJ disk, the ratio of fibroblasts to chondrocyte-like cells
varies by region as well, with the highest relative number of
chondrocyte-like cells present in the intermediate zone [47]
(Fig. 5(c)). GAGs were evenly distributed throughout young
equine menisci, whereas samples from older horses showed dis-
tinct positive and negative staining locations [60]. IHC deter-
mined the presence of hyaluronic acid backbone, keratan sulfate,
and chondroitin sulfate in the primate TMJ disk [57]. In addition,
collagen fibers in an equine knee meniscus model were shown to
be randomly organized in the distal and proximal surface layers
[60,61] (Fig. 5(b)), while the innermost layer exhibited circumfer-
entially aligned collagen fibers with parallel alignment in the red-
red region [60]. Polarized light microscopy [62] and scanning
electron microscopy [56] showed that collagen aligned primarily
circumferentially of the human and porcine TMJ disks, with the
intermediate zone showing alignment anteroposteriorly
(Fig. 5(d)). Finally, IHC showed greater type I collagen staining
than type II collagen staining throughout the porcine TMJ disk
[56].
Overall, histology and IHC are an adequate starting point for
confirming presence and distribution of cells, GAGs, and collagen
within fibrocartilage. While useful for the visualization of tissue
organization, histology and IHC are qualitative assays and should
be supported by sufficient sample sizes and quantitative assays,
such as biochemical and mechanical testing.
3.2 Biochemical Properties. Biochemical assays yield quan-
titative data that allow one to determine how similar properties of
tissue engineered fibrocartilage are when compared with those of
native tissue. DNA content can be quantified using, for example,
PicoGreen [48,63]. Sulfated GAGs are often quantified using
dimethyl methylene blue [48,54]. Collagen content can be meas-
ured by assaying for hydroxyproline [48,54,64]; a modified ver-
sion of this assay which excludes use of perchloric acid to
measure the collagen content has recently been published [64].
For quantification of specific types of collagen and GAG,
enzyme-linked immunosorbent assay is used [53,56]. Pyridinoline
content, a measure of collagen crosslinking, can also be quantified
with high performance liquid chromatographic assays [48,54,65].
Much like histology and IHC, many of these biochemical assays
can be performed to determine regional variation.
The knee meniscus extracellular matrix (ECM) is composed of
water, fibrillar components, proteoglycans, and adhesion glyco-
proteins. Water, collagen, and GAGs account for the majority of
components by mass and has been shown to be 72%, 22%, and
0.8%, respectively, in human menisci. The remainder of the tissue
is made up of DNA (0.12%) and adhesion molecules. The distri-
bution pattern of GAGs is as follows: 40% chondroitin 6-sulfate,
10–20% chondroitin 4-sulfate, 20–30% dermatan sulfate, and
15% keratan sulfate [66]. Collagen accounts for approximately
60–70% of the dry weight and includes types I–VI collagen [67].
Of these, type I collagen is by far the most predominant in the
meniscus, accounting for more than 90% of total collagen [68].
The outer two-thirds of bovine menisci is composed primarily of
type I collagen, whereas the inner one-third is 60% type II colla-
gen and 40% type I collagen [69]. Pyridinoline collagen crosslink-
ing has been shown to be highest in the inner region [70].
The biochemical composition of the TMJ disk is similar to the
meniscus, being composed of primarily collagen and GAGs.
Collagen is approximately 68.2% per dry weight in the porcine
TMJ disk [71], while GAG content ranges from 0.273 to 0.936%
per wet weight among species [51]. In a study on the
structure–function relationship of the Yucatan minipig TMJ disk,
the tissue showed regional variation in DNA content via Pico-
Green assay ranging from 0.024% to 0.041% per wet weight [48].
In a study on the porcine TMJ disk using enzyme-linked immuno-
sorbent assay to quantify GAGs, chondroitin sulfate was the most
abundant GAG found, compromising 74% of the total GAG con-
tent [56]. For regional collagen variation, the intermediate zone
had slightly more collagen per dry weight than the anterior and
posterior bands of the disk, while in the mediolateral direction the
central region contained significantly higher collagen than the lat-
eral region [71]. In the Yucatan minipig TMJ disk, pyridinoline
content was found to be significantly lower in the anterior and
posterior bands than in the lateral and medial regions of the disk
[48].
Biochemically, the knee meniscus and TMJ disk are similar
due to their fibrocartilaginous nature. Both have similar ranges for
collagen, GAG, and DNA content, and vary regionally as dis-
cussed previously. In addition, the meniscus and TMJ disk both
are composed of primarily type I collagen in relation to other col-
lagen types. Uniform biochemical characterization can be used for
fibrocartilages and is a required quantitative step after performing
histomorphological studies. Although biochemical assays may
provide insight into structure, they should be supplemented by
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mechanical testing to yield an understanding into fibrocartilage
function.
3.3 Mechanical Properties. Inasmuch as fibrocartilages bear
and distribute load, recapitulating the tissue’s mechanical proper-
ties is a critical design criterion. Tension and compression tests
are commonly used to derive target values. Uniaxial tensile testing
provides tensile Young’s modulus and ultimate tensile strength
(UTS) [48,52,54,63,72]. For compression properties, creep inden-
tation testing and incremental stress relaxation provide, among
other properties, aggregate modulus [73–75], coefficient of viscos-
ity [53,63,76], and instantaneous and relaxation moduli
[48,51,54,62,63]. In addition to aggregate modulus, Poisson’s
ratio and permeability are also obtained from creep indentation
testing [73,75,77]. These values can be derived from experimental
data using different models based on linear elasticity, viscoelastic-
ity including the standard linear solid model, poroelasticity, and
mixture theories including the biphasic model. In-depth descrip-
tions of these tests and their assumptions, performance, and
mechanical models are available in the literature [1,78–82]. While
no one testing modality is the gold standard for measuring
mechanical properties, tissue structure–function relationships dic-
tate which testing modality might be most informative when
measuring characteristic properties of a native tissue. For exam-
ple, the knee meniscus functions under compression, but its geom-
etry causes tensile forces to develop within the tissue, and, thus,
the tensile properties of a tissue engineered meniscus may be
more indicative of whether it will be effective in replacing
Table 1 Selected list of key publications for fibrocartilage tissue engineering
Authors Cell
source
Scaffold or scaffold-
free approach
Biochemical
stimuli
Mechanical
stimuli
Tissue
engineered
Kasemkijwattana
et al. [127]
Leporine MCs Monolayer Epidermal growth fac-
tor, IGF-1, bFGF,
PDGF, TGF-b1, trans-
forming growth factor
alpha, acidic fibroblast
growth factor, and
nerve growth factor
None Knee meniscus
Springer et al. [87] Human and Porcine
TMJ disk cells
and articular eminence
cells
Polyamide, polytetra-
fluoroethylene,
and PGA scaffold
None None TMJ disk
Detamore and
Athanasiou [97]
Porcine TMJ disk cells PGA scaffold IGF-1 Fluid-induced shear TMJ disk
Eifler et al. [136] Leporine MCs Monolayer None Oscillatory fluid flow-
induced shear
Knee meniscus
Bean et al. [95] Porcine TMJ disk cells PGA scaffold Ascorbic acid None TMJ disk
Almarza and
Athanasiou [98]
Porcine TMJ disk cells Monolayer and PGA
scaffolds
None Hydrostatic pressure TMJ disk
Aufderheide and
Athanasiou [109]
Bovine ACs and MCs Self-assembly None None Knee meniscus
Johns et al. [89] CCs, dermal fibroblasts,
TMJ disk cells
Self-assembly None None TMJ disk
Gunja et al. [125] Leporine MCs PLA scaffold TGF-b1 Hydrostatic pressure Knee meniscus
Huey and Athanasiou
[53]
Bovine ACs and MCs Self-assembly TGF-b1, C-ABC Tension and
compression
Knee meniscus
Huey and Athanasiou
et al. [76]
Bovine ACs and MCs Scaffold–self-assembly TGF-b1, C-ABC None Knee meniscus
Kalpakci et al. [106] Bovine Acs and MCs Self-assembly TGF-b1, IGF-1 None TMJ disk
Baker et al. [134] Bovine MSCs PCL scaffold TGF-b3 Cyclic tension Fibrocartilage
Hagandora et al. [100] Caprine CCs Poly (glycerol-sebacate)
scaffold
None None TMJ disk
Hadidi and Athanasiou
et al. [63]
Bovine ACs and MCs Self-assembly LPA None Knee meniscus
MacBarb et al. [124] Bovine ACs and MCs Self-assembly C-ABC, TGF-b1 None Fibrocartilage
Ahtiainen et al. [118] Leporine adipose-
derived MSCs
PLA scaffold TGF-b1 None TMJ disk
Moriguchi et al. [114] Porcine synovium-
derived MSCs
Cell sheet engineering BMP-2 None Knee meniscus
Makris et al. [54] Bovine ACs and MCs Self-assembly TGF-b1, C-ABC,
LOXL2
None Fibrocartilage
Higashioka et al. [110] Bovine ACs and MCs Self-assembly None None Knee meniscus
MacBarb et al. [135] Bovine ACs and MCs Self-assembly None Passive axial
compression
TMJ disk
Murphy et al. [103] Porcine CCs Self-assembly C-ABC, TGF-b1,
LOXL2
None TMJ disk
Murphy et al. [112] Porcine CCs Self-assembly TGF-b1, bFGF, PDGF None Fibrocartilage
Legemate et al. [117] Human bone marrow-
derived MSCs
PCL scaffold CTGF, TGF-b3 None TMJ disk
Warren et al. [121] None PCL scaffold None None Knee meniscus
Wang et al. [90] Rabbit TMJ disk cells
and synovium-derived
MSCs
PLGA scaffold TGF-b3 None TMJ disk
Note: Fibrocartilage tissue engineering studies were selected for their impact on the field. Authors, cell source, scaffold or scaffold-free approach, bio-
chemical stimuli, mechanical stimuli, and type of engineered tissue are listed for these studies.
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diseased tissue. Similarly, an analogous argument can be made for
the TMJ disk; though the disk functions primarily under compres-
sion, the end result is principally tensile strain fields in the ECM.
Values derived from mechanical testing of the meniscus and TMJ
disk are provided below.
Since both the knee meniscus and the TMJ disk exhibit anisot-
ropy, the mechanical properties depend on testing direction. The
knee meniscus exhibits more robust tensile mechanical properties
in the circumferential orientation rather than the radial due to the
generally circumferentially aligned collagen fibers; this holds true
throughout the depth of the tissue for the tissue’s Young’s modu-
lus [72]. The Young’s modulus is approximately 100–300MPa in
the circumferential direction and tenfold lower in the radial direc-
tion [2]. The meniscus has been shown to have an aggregate mod-
ulus of 100–150 kPa [75]. Incremental stress relaxation testing of
porcine knee menisci in synovial fluid has yielded instantaneous
and relaxation moduli for 20% strain of 2.37–6.75MPa and
0.07–0.15MPa, respectively, [83]. Values of mechanical proper-
ties can vary from species to species, as well as different testing
modalities [77,84].
The mechanical properties of the TMJ disk display anisotropic,
regional, and interspecies variations. Research on the Yucatan
minipig TMJ disk revealed that UTS and tensile Young’s modulus
of the central region was highest in the anteroposterior direction,
while the posterior band was stiffest and strongest in the mediolat-
eral direction, when determined by uniaxial tensile testing [48].
Creep indentation testing shows that the medial region of the TMJ
disk had the largest aggregate modulus at 28.96 12.3 kPa and
was found to be significantly higher than the anterior, posterior,
central, and lateral regions [73]. Instantaneous and relaxation
moduli for 20% strain in the Yucatan minipig TMJ disk were
found to be 216–1540 kPa and 20.5–57.5 kPa, respectively,
dependent on region [48]. Uniaxial tensile testing, creep indenta-
tion testing, and incremental stress relaxation all provide valuable
design criteria.
As tissues that undergo constant mechanical loading, the gold
standard for fibrocartilage functionality should accordingly be
mechanical testing. Appropriate characterization of not only
mechanical properties, but histomorphological and biochemical
properties, defines the design criteria to be used in tissue engineer-
ing studies. By defining native tissue values, tissue engineers
know what criteria they need to strive for and mimic within tissue
engineered fibrocartilages.
4 Tissue Engineering of Fibrocartilage
The tools developed to address the design criteria for tissue engi-
neering fall into the general category of cells, scaffolds, and sig-
nals. For fibrocartilage, of particular interest are the issues of
finding an appropriate cell source, choosing a scaffold or scaffold-
free approach, and identifying both biochemical and mechanical
stimuli as depicted in Fig. 3. A selection of the most impactful
studies outlined in Sec. 4 is summarized in Table 1. Sections
4.1–4.4 will include information on each of the aforementioned
components with a focus on approaches shown efficacious when
applied with a scaffold-free, self-assembling process of tissue
formation.
4.1 Cell Sources. Cell sources used in tissue engineering of
fibrocartilage vary from tissue-specific, terminally differentiated
cells to various stem cell types. In terms of tissue-specific cells for
tissue engineering of the knee meniscus, meniscus cells (MCs)
and hyaline articular chondrocytes (ACs) [53,63,76,85] have been
explored. For engineering the TMJ disk, TMJ disk cells [86–98],
articular eminence cells [87], mandibular condyle cells [99], cos-
tal chondrocytes (CCs) [89,100–104], ACs [54,102,105–107],
MCs [54,106,107], and dermal fibroblasts [89] have been
explored. Mesenchymal stem cells (MSCs) are the most heavily
examined stem cell population for tissue engineering of both
fibrocartilages. Factors to take into account for all cells are an
autologous versus allogeneic approach, coculture of cells, and var-
ious cell expansion technologies. For stem cells, additional con-
siderations include their theoretically infinite ability to expand
and suboptimal differentiation efficiency.
Autologous tissue-specific, terminally differentiated cells
directly from native tissue, such as TMJ disk cells or MCs, offer
the lowest risk of rejection, but sourcing can be a difficulty due to
insufficient healthy tissue. Other cell sources that can potentially
be derived in an autologous fashion for tissue engineered fibrocar-
tilages include cells from hyaline articular cartilage
[54,102,105–107], costal cartilage [89,100–104], tendon, and liga-
ment [108]. Autologous sources require two surgical procedures
on the same patient: one for harvest of the donor tissue and
another for implantation of engineered tissue. An allogeneic
approach, which employs cells from a nonself donor, mitigates
the issue of multiple surgeries for the patient and donor site mor-
bidity but is limited by a possible immune response and rejection.
Traditionally, articular cartilage has been considered to be an
immunoprivileged tissue; immune response against cells within
cartilage is rare due to the dense ECM [1]. A recent minipig study
showed minimal to no T cells, B cells, and macrophages within
allogeneic, tissue engineered fibrocartilage implants in the TMJ
disk [104], providing evidence that fibrocartilage, like hyaline
articular cartilage, may also be immunoprivileged.
Cocultures of cells have been explored to recreate the various
fibrocartilages that naturally contain different cell types and ECM
composition. For example, a one-to-one coculture ratio of ACs
and MCs [53,63,76], in comparison with other ratios, has been
shown to be optimal in reconstituting the native meniscal cross
section as well in providing adequate strength and stiffness [109].
Menisci that exhibit a more hyaline articular cartilage-like inner
region and a more fibrous outer region have been engineered by
seeding 100% ACs in the inner region and a one-to-one mix of
ACs to MCs in the outer region. This regionally variant meniscus
exhibited significantly higher compressive properties as well as
GAG per dry weight in the inner region, while the outer region
exhibited significantly higher circumferential tensile modulus and
collagen per dry weight [110]. These compositional and func-
tional properties mimic the biochemical and mechanical differen-
ces seen in native meniscus regions (Fig. 5(b)). For tissue
engineering the TMJ disk, AC and MC cocultures [54,106,107],
and CC and dermal fibroblast cocultures [89] have been exam-
ined. In AC and MC coculture, it was found that the presence of
ACs is required to maintain a cylindrical shape by reducing con-
traction [106]. CC and dermal fibroblast coculture was inferior to
CCs alone in terms of GAG content, total collagen, and type I col-
lagen [89]. Coculture of multiple cell sources remains a viable
option for creating more biomimetic tissue engineered fibrocarti-
lages. Clinically, this may be more difficult to achieve using an
autologous approach due to donor site morbidity and increasing
number of surgeries as previously discussed, but an allogeneic
approach might be appropriate if coculture were used.
Advances in cell expansion technologies that preserve cell phe-
notype, in combination with an allogeneic approach, have the
potential to mitigate the concerns that repeat surgeries, donor site
morbidity, and cell sourcing pose. For example, a combination of
transforming growth factor beta 1 (TGF-b1), basic fibroblast
growth factor (bFGF), and platelet-derived growth factor (PDGF)
increases the postexpansion chondrogenic potential of CCs by
increasing GAG content, altering the ratios of collagen types, and
improving compressive properties engineered using treated cells
[111]. After expansion, the phenotype of CCs can be preserved by
culturing them in three-dimensional (3D) aggregates [112].
During this aggregate redifferentiation process, application of
TGF-b1, growth differentiation factor 5 (GDF-5), and bone mor-
phogenetic protein 2 (BMP-2) also improves biochemical and
mechanical properties of neocartilage using treated cells [113].
This process allows defined expansion of cells and preservation of
phenotype by aggregate culture, and is extremely promising for
allogeneic approaches, increasing the impact one donor can have.
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Stem cells offer a solution to sourcing issues by having a theo-
retically infinite capability to expand. Synovial MSCs have been
explored for the repair of the meniscus in scaffold-free culture
methods [114] as well as via injection [115,116]. TMJ disk engi-
neering has used both MSCs from bone marrow [117] and adipose
tissue [118]. The current limitation of stem cells for tissue engi-
neered fibrocartilage formation lies in their suboptimal differentia-
tion protocols, which often lack efficiency (i.e., only a low
percentage of cells attain the target phenotype) and may result in
“chondrocyte-like” cells [119] that may not form mechanically
robust tissue engineered fibrocartilage. Additional concerns with
stem cell use include tumorigenic potential and possible xenoge-
neic culture components. While stem cells for tissue engineered
fibrocartilages have been used in research, their infinite expansion
potential has yet to be realized clinically due to lack of efficiency.
To summarize, an autologous approach may be the ultimate
goal because the cells are patient-specific, but not the most practi-
cal because the scarcity of healthy tissue remains an issue in these
already diseased patients. An allogeneic approach may be the
most translatable, especially with the advent of cell expansion
technologies and evidence that suggests fibrocartilage as immuno-
privileged. Allogeneic cells solve the issue of donor site morbidity
and repeated surgeries from autologous approaches. Using stem
cells may present the solution to the cell sourcing issue, but their
translatability is not yet realized due to efficiency and possible
tumorigenic potential. The selection of a cell source is among the
most important choices a tissue engineer can make and should be
well-informed by how a tissue engineered fibrocartilage will be
translated.
4.2 Scaffold and Scaffold-Free Methods. For 3D cell cul-
ture of tissue engineered fibrocartilage, both scaffold and
scaffold-free methods exist. Scaffolds can be used to direct cell
behavior by engineering specific biochemical and mechanical
cues into the biomaterial. In addition, scaffolds also allow imme-
diate cell attachment and provide support to the cells. Tissues can
also be engineered without scaffolds. Scaffold-free tissue engi-
neering is particularly useful when one wants to avoid scaffold
degradation products and stress shielding cells. With scaffold-free
methods, degradation products and residual byproducts from fab-
rication and their associated toxicity to the cells do not need to be
considered. Stress-shielding of cells via scaffolds is another con-
sideration that is removed in scaffold-free approaches. While scaf-
folds retain the ability to directly alter cell behavior and support
cells, for fibrocartilage tissue engineering, soluble and mechanical
signals have both shown efficacy in directing cell performance in
the absence of scaffolds.
A variety of scaffolding materials have been explored for tissue
engineered fibrocartilages including alginate [86], polycaprolac-
tone (PCL) [117], poly(glycolic acid) [86–88,93–98,105], decellu-
larized matrix [120], polyamide [87], polytetrafluoroethylene
[87], poly(glycerol sebacate) [100], type I collagen [91,99], poly(-
lactic acid) (PLA) [88,105,118], and poly(lactic-co-glycolic acid)
(PLGA) [90,117]. Considerations for scaffold formulations
include degradation rates and products, and fabrication methods
and resulting residual byproducts. Also, a recently added consid-
eration may be compatibility with 3D printing because the tech-
nology is conducive toward producing tissue engineered
fibrocartilages that are anisotropic and regionally variant, charac-
teristics important in the function of native fibrocartilages. For
example, anisotropic collagen alignment has been produced in 3D
printed menisci [121]. Similarly, a regionally variant TMJ disk
has been produced using 3D printing with PCL and spatiotempo-
ral delivery of PLGA microspheres with connective tissue growth
factor (CTGF) and transforming growth factor, beta 3 (TGF-b3)
encapsulated [117]. The wide range of scaffolds available for
knee meniscus and TMJ disk tissue engineering has been
reviewed elsewhere [2,45,122].
Self-organization and the self-assembling process are techni-
ques that generate 3D structures in a scaffold-free manner, but
they are distinctly different. Self-organization is defined as any
technique that produces biomimetic tissues with use of external
forces or energy whereas the self-assembling process is defined as
a spontaneous organization of cells that mimics native tissue
structures without external forces or energy. Self-assembly occurs
via the minimization of free energy through cell-cell interactions.
Examples of self-organization include cell sheet engineering and
bioprinting of cells. Self-assembly is used across multiple tissue
types, including fibrocartilage. Self-assembly addresses considera-
tions of scaffold-based methods by the creation of robust tissue
engineered fibrocartilages that can immediately bear load and do
not shield the cells from various stresses present in the joint envi-
ronment [123].
4.3 Biochemical Stimuli. Biochemical stimuli are used to
target cells and ECM molecules to improve mechanical proper-
ties. This can occur, for example, via increased production of
ECM, improved collagen fiber alignment, or increased collagen
crosslinking. For the production of scaffold-free, tissue engineered
fibrocartilage, prior studies have applied a variety of growth fac-
tors including TGF-b1, small molecules such as ascorbic acid and
phospholipid lysophosphatidic acid (LPA), and matrix modifying
enzymes chondroitinase ABC (C-ABC) and lysyl oxidase-like 2
(LOXL2) separately and in combination.
Growth factors have been extensively studied for tissue engi-
neered fibrocartilages. TGF-b1 [54,76,124,125], TGF-b3
[88,90,117], CTGF [117], PDGF [92,126,127], bFGF
[92–94,127], insulin-like growth factor 1 (IGF-1) [88,92–94,
106,126,128], and epidermal growth factor [126,127] are exam-
ples of growth factors that have shown various levels of efficacy
in enhancing tissue engineered fibrocartilage formation. For
example, TGF-b1 has been shown by microarray analysis to pro-
mote AC synthesis of ECM [129] and has shown similar effects in
fibrocartilage studies [54,76,124,125]. Small molecules such as
LPA and ascorbic acid have been studied as well. LPA increased
values of tensile Young’s modulus from 2476 89 kPa in control
groups to 5036 159 kPa in stimulated groups, along with collagen
fiber density and organization in meniscal tissue engineered fibro-
cartilage [63]. Ascorbic acid is a vital component to cell culture
media and was found to be optimal at 25 lg/mL for cell concen-
tration, collagen deposition, and aggregate modulus values in a
TMJ disk model [95]. Enzymes such as the GAG-depleting
enzyme C-ABC and the collagen crosslinking enzyme LOXL2
have been previously shown to have a positive effect on mechani-
cal properties. Specifically in articular cartilage, C-ABC has been
shown to increase tensile properties exhibiting an increase of
121% and 80% compared to untreated controls in UTS and
Young’s modulus, and allow for more type II collagen deposition
as a result of GAG depletion [130]. For the native knee meniscus,
LOXL2 has been shown to increase tensile properties approxi-
mately 1.9-fold during explant culture [131]. More thorough and
extensive reviews of various biochemical stimuli and their effects
on tissue engineered fibrocartilage are available in the literature
[2,132,133].
Various growth factors and enzymes have also been used in
combinations to create synergistic effects between increased ECM
and more mature ECM. For example, increases in radial tensile
moduli by fivefold over untreated controls of meniscal tissue engi-
neered fibrocartilage were observed over untreated controls when
a combination of TGF-b1 and C-ABC was applied [76]. A TGF-
b1 and C-ABC combination can be used to tissue engineer other
fibrocartilages as well because it has been observed to increase
both tensile Young’s modulus and UTS over unstimulated con-
trols, reaching the lower range of native values [124]. Combining
TGF-b1, C-ABC, and LOXL2 treatments during the culture of tis-
sue engineered fibrocartilage led to further significant improve-
ment of tensile Young’s modulus and UTS by 245% and 186%,
respectively, [54]. This combination has also been used to
enhance mechanical properties and integration of TMJ disk tissue
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engineered fibrocartilages, resulting in values of tensile Young’s
modulus of over 6MPa and compressive instantaneous modulus
of over 1200 kPa after 8weeks in culture [103]. The biochemical
stimuli that have been used and their varying efficacy might war-
rant additional research into novel, synergistic combinations of
stimuli.
4.4 Mechanical Stimuli. Mechanical forces exerted naturally
on native fibrocartilage are critical in tissue development and
homeostasis. Native fibrocartilages experience tension, compres-
sion, hydrostatic pressure, and shear, and each of these forces has
been applied to tissue engineered fibrocartilage as well. Prior tis-
sue engineering studies involving mechanical loading either alone
or combined with biochemical stimuli have resulted in significant
increases of mechanical properties and also anisotropy.
Tension and compression are two commonly applied mechani-
cal stimuli for tissue engineered fibrocartilage. While typically
applied as separate stimuli, in fibrocartilage they often work
together. For example, in the meniscus when a compressive load
is applied, tensile strains develop due to the meniscus’ wedge
shape [2]. Meniscal tissue engineered fibrocartilage comprised of
a nanofibrous matrix seeded with MSCs was subjected to dynamic
tensile loading, leading to an increase in tensile modulus by 16%
[134]. Independently of tension, passive axial compression of
0.1N in a TMJ disk model has been shown to increase collagen
and GAG content significantly as well as increase relaxation and
tensile Young’s modulus by 96% and 255%, respectively, over
controls [135]. Combining TGF-b1 and C-ABC treatments with
direct tension-compression loading during culture significantly
increased instantaneous modulus (threefold), relaxation modulus
(twofold), and tensile Young’s modulus in the radial (sixfold) and
circumferential (fourfold) directions of self-assembled meniscal
fibrocartilage. The direct compression-tension bioreactor for
menisci was fabricated such that the platens matched the curved
surface and elliptical shape of the meniscal tissue engineered
fibrocartilage, ensuring simultaneous compression and tension
stimulation [53].
Although less often examined, hydrostatic pressure and shear
also have been used to tissue engineer fibrocartilage. When sub-
jected to a hydrostatic pressure loading regimen, PLA scaffolds
seeded with MCs exhibited increases in ECM production exhibit-
ing threefold higher GAG deposition and fourfold higher collagen
deposition [125]. In a study on TMJ disk cells on PLA scaffolds,
hydrostatic pressure was applied at 10MPa either intermittently at
1Hz or continuously for 4 h a day. Type I collagen was highest in
the continuous stimulation group compared to the nonloaded and
intermittent stimulation groups [98]. Fluid shear, while typically
regarded as being a detrimental mechanical stimulus for the main-
tenance of a chondrocyte-like phenotype, may merit exploration
for tissue engineered fibrocartilages. Exposing MCs to oscillatory
fluid flow in parallel plate flow chambers has been shown to
upregulate calcium signaling and GAG production [136]. Use of a
rotating bioreactor in TMJ disk cell culture led to earlier and
greater contraction compared to the control. This resulted in a
denser ECM and cell composition; however, total ECM content
and compressive stiffness were not significantly different [97].
Overall, there is currently not enough evidence to conclude
whether fluid-induced shear is beneficial for tissue engineered
fibrocartilages.
Using mechanical stimuli on tissue engineered fibrocartilages is
an effective way to increase ECM production and organization,
which subsequently results in more robust mechanical properties.
This in conjunction with a biochemical stimulus regimen may
also lead to synergistic effects, further enhancing tissue engi-
neered fibrocartilage functionality. While there are limited studies
using mechanical stimuli on tissue engineered fibrocartilage,
many of the stimuli discussed here have been extensively studied
for hyaline articular neocartilage in other reviews [137]. Further
examination of mechanical stimulus regimens for tissue engi-
neered fibrocartilage is warranted because specific application
times and load amounts can have either beneficial or detrimental
effects.
4.5 Toward Tissue Engineering the Fibrocartilage Spec-
trum. Due to the spectrum of fibrocartilage structures in the
body, each tissue engineering strategy will be slightly different.
The outlined studies here provide insight into current tissue engi-
neering methodology for the knee meniscus and the TMJ disk, but
the approach to the pubic symphysis or annulus fibrosus of the
intervertebral disk might require different methods. However, the
concepts discussed in the prior sections can be used generally to
approach tissue engineered fibrocartilages in a uniform manner.
One way to tailor the tissue engineering approach used is applica-
tion of multiple types of stimuli, varying the cell source, or using
a different scaffolding or scaffold-free approach. Taking these
considerations into account is critical when designing and carry-
ing out tissue engineering studies. By properly considering these
factors, a translational approach can be created and quickly shifted
from basic research to preclinical animal models. This can eventu-
ally result in transition to clinical trials and a tangible product that
can be put through the FDA paradigm (Fig. 4).
4.6 Evaluation of Tissue Engineered Fibrocartilage. Histo-
morphological, biochemical, and mechanical testing of tissue
engineered fibrocartilage yields properties that can be compared
with those of native tissue to determine whether the tissue engi-
neering design criteria have been met. All evaluation methods out-
lined in Sec. 3 can be applied to tissue engineered fibrocartilage
(Fig. 3). The quantitative values derived from these assays can be
statistically compared to each other to determine whether one tis-
sue engineering modality is more efficacious than another. Quan-
titative values can also be normalized to native tissue values in the
form of a functionality index (FI), Eq. (1). The FI accounts for
biochemical and mechanical properties found in native tissue and
normalizes tissue engineered values to those of native tissue. The
FI provides a quantitative value that reflects the overall quality of
tissue engineered constructs that can be compared to each other.
For example, the TMJ disk FI accounts for GAG, total collagen,
instantaneous modulus values, relaxation modulus values, tensile
Young’s modulus values, and UTS values. The FI in Eq. (1)
weighs each of the metrics equally [104,138]. The FI varies
between 0% and 100%, where 100% is the value of native
fibrocartilage.
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Similarly, a knee meniscus FI might include similar components
with the addition of radial tensile modulus to account for the tis-
sue’s anisotropy.
It is important to note that a perfect FI of 100% is not necessar-
ily needed for proper functioning of tissue engineered fibrocarti-
lage in vivo. For example, an FI of 42% was adequate for a TMJ
disk thinning model in the Yucatan minipig, where the implanted
disk exhibited mechanical robustness in situ, adaptively remod-
eled, and improved integration stiffness [104]. For specific models
of fibrocartilage injury, appropriate FI values need to be estab-
lished for the translation of tissue engineered fibrocartilages that
researchers can aim for.
It is important to note that the tissue engineering approach must
meet established design criteria (Fig. 3). As discussed, this can be
measured by an index such as an FI, but other characteristics such
as cell morphology and tissue anisotropy need to be evaluated
qualitatively or using other measurements. If the tissue engineer-
ing approach does not meet design criteria in any of these catego-
ries, the process can be reiterated, and the approach can be
modified to meet the target design criteria (Fig. 3). Upon meeting
design criteria for the tissue engineering phase, researchers still
need to demonstrate safety and efficacy in preclinical animal mod-
els and approved by the FDA before a tissue engineered fibrocarti-
lage can be marketed as a therapy.
5 Toward Translation of Tissue Engineering
Tissue engineered fibrocartilage safety and efficacy must first
be reviewed and cleared by the FDA before it can be marketed for
clinical use. After tissue engineering studies, tissue engineered
fibrocartilages should be demonstrated as safe and effective in ani-
mal models before examining the products’ effects in humans.
This section will present the FDA paradigm (Fig. 4), diving into
preclinical animal models and clinical trials, and discussing con-
siderations for both. Because there is lack of approved tissue engi-
neered fibrocartilage products existing for repair or replacement,
this section uses existing articular cartilage guidance as a way to
infer how tissue engineered fibrocartilage products might be regu-
lated. This section closes with a discussion on areas where addi-
tional guidance from the FDA is desired, for example, through the
creation of a fibrocartilage guidance document analogous to that
which exists for articular cartilage.
5.1 The Food and Drug Administration Paradigm. Tissue
engineered fibrocartilage products will be regulated as HCT/Ps, a
category of products containing or consisting of human cells or
tissues intended for implantation, transplantation, infusion, or
transfer into humans [4]. Much like tissue engineered products for
hyaline articular cartilage [5], tissue engineered fibrocartilage
products will be regulated through two centers of the FDA: the
Center for Biologics Evaluation and Research (CBER) and/or the
Center for Devices and Radiological Health (CDRH). CBER and
CDRH co-authored the FDA guidance document for products
intended to repair or replace hyaline articular cartilage [5], and
this document can give insight into how tissue engineered fibro-
cartilage products might be regulated given similarities between
the two tissue types.
If an HCT/P is minimally manipulated, intended for homolo-
gous use, and uncombined with another object, then it is only sub-
ject to regulation under Section 361 of the Public Health Service
(PHS) Act and title 21 of the Code of Federal Regulations Section
1271.3(d)(1). These HCT/Ps are referred to as 361 products and
do not require premarket approval. Examples of 361 products
include bone (including demineralized bone), ligaments, tendons,
and cartilage, which may have been sourced from cadaveric tis-
sues. In terms of specific fibrocartilage products, cadaveric fibro-
cartilaginous tissue to be used as an allograft such as the knee
meniscus and TMJ disk would fall under the category of 361 prod-
ucts. Otherwise, HCT/Ps are regulated as drugs, and/or biological
products under Section 351 of the PHS Act and/or the Federal
Food, Drug, and Cosmetic (FD&C) Act and are referred to as 351
products. Examples as provided by the FDA include cultured car-
tilage cells, cultured nerve cells, and gene therapy products. For
fibrocartilage, expanded TMJ disk cells or MCs might fall under
this category as well as tissue engineered fibrocartilage cultured
using the self-assembling process.
Under the CDRH, products are regulated as devices under the
FD&C Act. Human collagen and preserved umbilical cord vein
grafts are in this classification. Biomaterial scaffolds without com-
bination of cells for fibrocartilage repair or replacement may fall
into this category. In addition, certain HCT/Ps can be classified as
combination products by the Office of Combination Products and
assigned to CBER or CDRH for primary jurisdiction. One exam-
ple is cultured cells on synthetic membranes or combined with
collagen. This product has potential to be regulated as a device or
biological product, but is currently under review and may be regu-
lated by CBER under device or 351 product regulations [4]. Tis-
sue engineered fibrocartilage with use of a scaffold and seeded
chondrocytes may fit into this category. Due to the many ways
and materials with which fibrocartilage can be engineered, the
FDA’s classification of tissue engineered fibrocartilage products
can vary. Consultation with the FDA is recommended if there is
confusion as to the categorization of a specific tissue engineered
fibrocartilage product.
Following product classification, a sponsor seeking FDA
approval may consult guidance documents and the regulation of
other approved products to determine data that need to be col-
lected and submitted to the FDA. Guidance documents specifi-
cally for tissue engineered fibrocartilage products have not been
published, but a guidance document has been published for prod-
ucts intended for repair or replacement of hyaline articular carti-
lage, which shares many similarities with fibrocartilage. In
addition, autologous cultured chondrocytes on a porcine collagen
membrane is an approved cellular and gene therapy product
whose pathway to regulatory approval may offer insights for tis-
sue engineered fibrocartilage products. The guidance document
for articular cartilage products contains nonbinding recommenda-
tions to the industry on preparation and submission of investiga-
tional device exemption (IDE) and/or an investigational new drug
(IND) application. Recommendations for classification of prod-
ucts, preclinical data, biocompatibility testing, and clinical study
protocols are described. For example, goats, sheep, and horses are
listed as the most frequently used large animal models for testing
biological response, durability, toxicology, dose response, lesion
size and location, appropriate endpoints, and use of arthroscopic
or MRI imaging evaluations for articular cartilage repair [5].
Fibrocartilage large animal models are similar to the ones
employed for articular cartilage with the addition of the minipig,
farm pig, and dog [43,46,48,139]. For clinical trials, design, con-
trols, study populations, endpoints, implantation procedures, and
patient follow-up are all discussed as well [5]. Examples of meas-
ures that may be used to assess endpoints for articular cartilage
products are the Knee Injury and Osteoarthritis Outcome Score
(KOOS), IKDC Subjective Knee Evaluation Form-2000, and
Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) [5]. For fibrocartilage within the knee such as the
meniscus, these scoring systems might be adaptable while the
TMJ disk fibrocartilage might need new indices created. This
motivates the creation of a standardized scoring system for fibro-
cartilages throughout the body.
Guidance documents as well as meetings with the FDA help to
provide clarity on the process by which a product receives FDA
approval, and this process is briefly depicted in Fig. 4. Tissue
engineering studies yield a product candidate that is then tested in
preclinical animal studies to generate data for submission of an
IDE and/or IND application dependent on product classification.
An IDE/IND is necessary for clinical trials. Clinical trials are con-
ducted in phases, and considerations for clinical trials include
defining and measuring endpoints, the surgical procedures used,
and patient follow-up. Upon completion, data from the trials are
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submitted via a premarket approval and/or a biologics license
application (BLA) to the FDA. These applications will be under
review for a time-period known as the premarket application
phase where the FDA reviews the data for safety and efficacy of
the product. FDA approval allows the product to be marketed.
Product safety and efficacy continues to be monitored in the post-
marketing phase, sometimes referred to phase IV clinical trials.
For more information on the FDA paradigm and general transla-
tion of tissue engineering products, readers are directed to a recent
review [140].
5.2 Preclinical Animal Models. Currently, there are limited
approved fibrocartilage HCT/Ps or clinical trials. Putting this in
context of Fig. 4, the general state of fibrocartilage tissue engi-
neering currently straddles the phases of tissue engineering studies
(discussed in Sec. 4) and preclinical animal studies. Animal stud-
ies provide preclinical data that show how the product functions
in vivo. Animal studies are used to assess biological responses,
the durability of repair, toxicology, dose response, lesion size and
location, appropriate endpoints mirroring those to be used in
humans, and use of arthroscopic and/or MRI evaluations as has
been previously outlined [5]. Aside from examining the host, test-
ing modalities outlined in Sec. 3 should also be applied to the tis-
sue engineered fibrocartilage implant both before and after
implantation. Data on how the implant’s biochemical, mechanical,
and cellular properties change or remain the same will inform the
success of the tissue engineering process and implant performance
in vivo. Similar to using the FI to optimize tissue engineering pro-
cedures, the FI can be used for in vivo studies to determine, for
example, implant properties that correlate with a durable repair
response. It is worth noting that, unlike suggestions found in the
hyaline articular cartilage product guidance document which only
touches on compressive testing modalities [5], an appropriate FI
for fibrocartilage should include both tensile and compressive
properties due to the way fibrocartilage functions. Correlation of
the implant’s FI to host response might further inform eventual
release criteria for the manufacturing of tissue engineered fibro-
cartilage products. An index such as the FI for general fibrocarti-
lage tissue engineering would be informative to the field and
allow comparison of various tissue engineering strategies for dif-
ferent fibrocartilages.
Ideally, preclinical studies in animals would test a version of
the product that is identical to that which will be used in clinical
studies. Investigating a product that contains human cells in ani-
mal models could require immunosuppressive agents to avoid
rejection upon implantation, and this can be difficult if not impos-
sible to implement in certain animal models. Recently, a review
on experimental immunosuppression and immunomodulation has
been published and may help provide strategies by which these
can be applied to xenogeneic or allogeneic animal models [141].
Alternatively, one can test an analogous cellular product in terms
of cellular characteristics and biological activity, derived from the
animal species used in studies in an allogeneic strategy.
Preclinical data can be obtained from a combination of small
and large animal studies. Small animal models, such as rodent and
leporine models, allow for larger, more economical studies. How-
ever, for fibrocartilage injuries, surgical procedures in small ani-
mals may become difficult due to small joints that provide little
space for operating. Translational applications in humans for tis-
sue engineered fibrocartilage are best modeled in large animals
that replicate human biomechanics as much as possible. As noted
previously, goats, sheep, and horses are recommended for examin-
ing hyaline articular cartilage repair [5], but other species may
suit fibrocartilage studies better. For example, menisci in pigs and
sheep are most similar to humans’ in terms of size and proportion
[44], while ovine menisci are also similar to humans’ in terms of
composition and biomechanics [142]. For the TMJ disk, the Yuca-
tan minipig has also been deemed a suitable comparative model to
humans in terms of its structure–function relationships [48], and
has seen success in a regeneration study by our group which used
CCs to tissue engineer allogeneic TMJ disk fibrocartilage [104].
As such, the pig (including minipigs) and sheep may prove useful
as large animal models for fibrocartilage studies, especially in
those regarding the knee meniscus and TMJ disk.
For each animal model, details such as the specific surgical pro-
cedure for implanting the fibrocartilage product, how that surgical
procedure may translate to human studies, how the study models
particular indications, and specialized recovery or postoperative
care must all be considered. For example, in a recent study where
a focal thinning defect model was used, there was careful consid-
eration of the minipig’s postoperative diet [104]. After TMJ sur-
gery, a diet consisting of mainly soft foods or liquids as opposed
to hard foods is more amenable to repair. Thus, even if an animal
model displays anatomical and functional similarities to humans,
it does not automatically mean that the model should be chosen if
surgical, husbandry, or other aspects listed previously cannot be
adequately developed for the animal.
5.3 Clinical Trials. After obtaining preclinical data and
approval of an IDE and/or IND, clinical trials can commence.
Phase I and II trials commonly contain small patient cohorts com-
pared to phase III trials. Phase I trials are meant to determine
safety and dosage of the tissue engineered fibrocartilage product.
Phase II trials determine product efficacy and possible side effects
of fibrocartilage therapies. Phase III trials examine long-term
safety and efficacy in larger patient cohorts.
While animal models may inform endpoints in humans, it is
ultimately clinical trial data that will be used in final approval for
market. Because explanting implanted tissue engineered fibrocar-
tilages would impair function, it is oftentimes not possible to test
human implant properties as done in preclinical animal models.
Therefore, endpoints are often defined via subjective scales, such
as pain and range of motion testing. Development of a standard
fibrocartilage scoring system would be of great value to clinical
trials of tissue engineered fibrocartilage products. Arthroscopic
evaluation, histologic evaluation, serological assessments for
inflammation, and imaging might also inform endpoints [5].
Considerations that ensure successful repair in animals should
likewise be thought out in clinical trials. For example, surgical
approaches such as technique and postoperative care must be
standardized and inspected particularly in multicenter trials to
minimize center-to-center variability. In addition, for the indica-
tion that a tissue engineered fibrocartilage product intends to treat,
participants that undergo current gold standard treatment should
also be enrolled to demonstrate the tissue engineered product’s
efficacy over standard of care. For example, for late-stage pathol-
ogy of the TMJ disk such as perforation, either discectomy or total
joint reconstruction is often indicated. These two clinical treat-
ments will ultimately be two treatments that a tissue engineered
TMJ disk may be compared to. Finally, follow-up of treatment
with tissue engineered fibrocartilage will be required in these
patient populations. It is common for the FDA to require safety
and efficacy data over a number of years to compare short-term
results of the tissue engineered fibrocartilage to current clinical
treatments. The FDA will also use these data to evaluate claims of
the product. For successful execution of clinical trials, these con-
siderations should be taken into account to gain FDA approval for
commercialization.
5.4 Future Directions. Tissue engineering approaches of
fibrocartilage have improved markedly within the last decade,
allowing for the fabrication of more mechanically robust tissue
engineered fibrocartilages. However, as previously discussed, cur-
rent clinical treatments that address indications such as meniscal
tears and TMJ disk perforation require follow-up clinical proce-
dures within a short time frame. In addition, there is a lack of tis-
sue engineered fibrocartilage products on the market. This may be
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due, in part, to a dearth of clarity on how tissue engineered fibro-
cartilage products can be translated.
Outlined here is the FDA paradigm as seen through current doc-
umentation and resources with numerous specific considerations
for preclinical animal models and clinical trials of potential fibro-
cartilage products. The considerations discussed here are just an
example of what must be taken into account when going through
the FDA paradigm. Clarification of important considerations and
guidelines must occur in order to allow translation of tissue engi-
neered fibrocartilage products. As such, the field should gravitate
toward studies that have translational implications and perhaps
ask for the FDA to create a guidance document similar to the one
that exists for articular cartilage products [5]. A guidance docu-
ment would provide recommendations to researchers and stream-
line translational advances to tissue engineered fibrocartilage
products used in the clinic.
There are a number of remaining questions and concerns sur-
rounding the creation of such a guidance document. One concern
is how such a document can be created when there are multiple
types of fibrocartilaginous tissues in the body varying in function.
As examined earlier, there are actually significant similarities
between meniscus and TMJ disk pathologies and current clinical
treatments that allow for similar tissue engineering approaches to
be used for both. These tissues are just two fibrocartilage exam-
ples. Hence, discussion and exploration of other fibrocartilaginous
tissues like the pubic symphysis and annulus fibrosus of the inter-
vertebral disk are warranted. Along those same lines, critics might
question the inclusion of numerous different pathologies, ranging
from early to late-stage, within one document. One option might
be to focus in on pathologies that are associated with degeneration
of the tissue where tissue engineering might be able to bolster the
early to midstage degeneration via repair or replace the tissue
completely for late-stage pathologies. Finally, as discussed with
the FDA paradigm, clinical endpoints must be measured. A major
hurdle remaining is the development of standardized indices or
measurement systems for fibrocartilage in general. Evaluating tis-
sue engineered fibrocartilage by an FI was suggested for tissue
engineering and preclinical studies but remains a question for
measurement of clinical endpoints in phased human trials.
In summary, tissue engineering of fibrocartilage addresses the
limitations of current clinical treatments. There has been limited
translation of tissue engineered fibrocartilage products from the
bench to the bedside. Throughout the FDA paradigm, there are
many considerations to be included in the guidance document as
discussed earlier. However, there are still several hurdles and
remaining questions before the creation of a fibrocartilage guid-
ance document analogous to that which exists for articular carti-
lage can come to fruition.
6 Conclusion
This review has highlighted tissue engineering of fibrocartilage,
using the knee meniscus and TMJ disk as primary examples.
Anatomy, function, epidemiology, pathologies, and current clini-
cal treatments were reviewed to elucidate the need for tissue engi-
neered solutions that are both biochemically and mechanically
reminiscent of native tissue. Prior to tissue engineering fibrocarti-
lage, design criteria must be attained via characterization of native
tissue in the species of interest. Design parameters such as cell
sourcing, scaffold versus scaffold-free methods, as well as bio-
chemical and mechanical stimuli alone or in combination were
discussed to create a fibrocartilage spectrum. Evaluation of the
resultant tissue engineered fibrocartilages was also examined for
comparison to previously characterized properties of native tissue.
Navigation of the FDA paradigm was discussed to motivate the
translation of studies from laboratory bench to bedside in the
clinic. We have recommended collaboration and open communi-
cation with the FDA to create a fibrocartilage guidance document
analogous to that which exists for articular cartilage. Regulation
of tissue engineered fibrocartilage and considerations for
preclinical animal models and clinical trials were highlighted to
encourage standardization among the field. Ultimately, this review
looks to the future of tissue engineered fibrocartilage products,
which are the culmination of decades-long research efforts. While
there remains much to be accomplished, the field is now closer
than ever to alleviating prominent fibrocartilage conditions.
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Nomenclature
ColN ¼ native collagen content
ColTE ¼ tissue engineered collagen content
EN
T ¼ native tensile Young’s modulus
EN
20i ¼ native instantaneous modulus
EN
20r ¼ native relaxation modulus
ETE
T ¼ tissue engineered tensile Young’s modulus
ETE
20i ¼ tissue engineered instantaneous modulus
ETE
20r ¼ tissue engineered relaxation modulus
FI (TE|N) ¼ functionality index of tissue engineered fibrocarti-
lage in relation to native tissue
GAGN ¼ native glycosaminoglycan content
GAGTE ¼ tissue engineered glycosaminoglycan content
UTSN ¼ native ultimate tensile strength
UTSTE ¼ tissue engineered ultimate tensile strength
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